復星醫藥(02196.HK):復宏漢霖(02696.HK)與Essex合作研發眼病新藥
復星醫藥(02196.HK)公布,子公司復宏漢霖(02696.HK)計劃與Essex Bio-Investment合作研發新藥HLX04,用於濕性年齡相關性黃斑變性等眼病治療,並於全球範圍生產及商業化銷售。
根據協議,復宏漢霖將主要負責該新藥的臨床前及臨床試驗、Essex 將主要負責許可產品的上市申請。復宏漢霖、Essex將按照20%、80%的比例承擔合作開發的投入。根據約定,Essex應向復宏漢霖支付至多2,500萬美元首付款及研發裡程碑付款,並在商業化後支付銷售裡程碑付款及銷售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.